---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-001858"
form_type: "8-K"
ticker: "ACRS"
cik: "0001557746"
company_name: "Aclaris Therapeutics, Inc."
filed_at: "2023-01-06T23:59:59+00:00"
generated_at: "2026-06-20T18:47:21.195951+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Aclaris finalizes CEO and CFO employment agreements; Manion $600k base, Balthaser $444k base

## Summary
- Douglas Manion appointed CEO effective Jan 1, 2023 with annual base salary of $600,000 and target bonus of 55% of base.
- Kevin Balthaser appointed CFO effective Jan 1, 2023 with annual base salary of $444,000 and target bonus of 40% of base.
- Both employment agreements have initial two-year term with automatic renewal; severance includes 12-month base salary and COBRA in non-change-of-control terminations.
- Under change of control termination, Manion receives additional 6 months salary and 150% target bonus; Balthaser receives additional target bonus; both get full equity acceleration.

## SEC filing metadata
- accession: 0001104659-23-001858
- form_type: 8-K
- ticker: ACRS
- cik: 0001557746
- company_name: Aclaris Therapeutics, Inc.
- filed_at: 2023-01-06T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1557746/000110465923001858/0001104659-23-001858-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1557746/000110465923001858/tm232381d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-001858
- JSON: https://secwatch.observer/filing/0001104659-23-001858.json
- Plain text: https://secwatch.observer/filing/0001104659-23-001858.txt

## Key facts
- Executive change
  Douglas Manion was appointed as Chief Executive Officer at Aclaris Therapeutics, Inc..
  - Action: appointed
  - Role: Chief Executive Officer
  source text: appointed Douglas Manion as the Company’s Chief Executive Officer, effective as of January 1, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1557746/000110465923001858/0001104659-23-001858-index.htm
- Executive change
  Kevin Balthaser was appointed as Chief Financial Officer at Aclaris Therapeutics, Inc..
  - Action: appointed
  - Role: Chief Financial Officer
  source text: appointed Kevin Balthaser as the Company’s Chief Financial Officer, effective as of January 1, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1557746/000110465923001858/0001104659-23-001858-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.